Dengue Vaccines Market Analysis Report 2021-2031 | Key Players like Sanofi Pasteur Limited, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., GlaxoSmithKline Plc, GeneOne Life Science Inc. and so on

The global dengue vaccines market is poised to expand at a staggering double-digit CAGR through 2031, surpassing US$ 1 billion during the forecast period, concludes ESOMAR-certified market research company Future Market Insights (FMI) in its recently published report. Growth is majorly underpinned by the rising incidence of dengue fever across endemic regions.

According to the World Health Organization, 70% of the total disease burden is prevalent across Asia, thereby encouraging prominent pharmaceutical giants to increase inroads across such countries as India, the Philippines and Japan. Presently, the market appears highly consolidated, attributed to the existence of just one effective vaccine candidate- Sanofi Pasteur’s Dengvaxia®.

However, future pipeline projects by other prominent giants is likely to enhance the scope of the market. For instance, since 2018, Sun Pharmaceuticals Ltd. is working on the DSV4 vaccine which is expected to provide protection against dengue infection to previously unaffected patients. Likewise, since 2017, the Serum Institute of India has been developing the VIS513 monoclonal antibody which have exhibited positive outcomes in neutralizing the dengue virus in animal mode studies, with a breakthrough expected in 2021.

Request For Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1763

Key Takeaways from FMI’s Dengue Vaccines Market Study

  • CYD-TDV (Dengvaxia) to retain its dominance in the global dengue vaccines market, alternative candidates are under investigation
  • By end-user, governments are expected to pivot majority of dengue vaccines demand in forthcoming years
  • Major pharmaceutical giants are concentrating on developing live attenuated dengue vaccines amid their perceived greater effectiveness
  • US to experience escalating growth, amid ongoing clinical trials to develop more vaccine candidates
  • Mexico is expected to emerge as an attractive destination for dengue vaccine manufacturers
  • Rising health & hygiene initiatives to spur dengue vaccines development across India
  • Brazil to pivot most of the Latin American dengue vaccine market, amid an extremely high prevalence rate

“Present dearth of multiple vaccine candidates is likely to generate credible opportunities for prominent pharmaceutical corporations to increase R&D funding for new clinical trials and licenses, leading to an expansion of the global dengue vaccines market,” says the FMI analyst.  

Competitive Landscape

Sanofi Pasteur Limited, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., GlaxoSmithKline Plc, GeneOne Life Science Inc., Medigen Vaccine Biologics Corporation, Panacea Biotec Limited, Sun Pharmaceutical Industries Ltd, Serum Institute of India Pvt. Ltd. and Biological E Ltd. are some prominent dengue vaccines manufacturers as profiled by FMI.

Prominent players are looking to constantly introduce new vaccine candidates in order to remain afloat in the market. In 2020, Medigen Vaccine Biologics Corporation (MVC) completed the phase II study for the TetraVax-DV dengue vaccine in Taiwan, thereby establishing the safety and efficacy of the candidate. It subsequently initiated phase III of the study.

Likewise, in September 2020, Panacea Biotec Limited completed of its Phase I/II study of its novel, tetravalent recombinant chimeric Dengue candidate vaccine christened DengiAll. After a single dose, over 80% of the participants exhibited more than a trivalent response and around 95% showed multivalent response.

More Insights on the Global Dengue Vaccines Market

In its latest report, FMI offers an unbiased analysis of the global dengue vaccines market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product (CYD-TDV (Dengvaxia)) and end-user (hospitals, government institutes and NGOs) across seven regions (North America, Latin America, APEJ, Western Europe, Eastern Europe, Middle East & Africa and Japan).

Any Queries, ask us @ https://www.futuremarketinsights.com/ask-question/rep-gb-1763

Reasons to Buy the report

  • We provide authentic and detailed an analysis on various market trends to enable businesses to make informed and beneficial decisions to attain competitive edge over key players.
  • Our analysts provide detailed market segmentation along with meaningful insights and extensive reports that other companies fail to include.
  • The report includes accurate analysis of the market and the current developing trends affecting the growth. FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. This ensures that the data collected is from highly reliable sources.

Download Report TOC @ https://www.futuremarketinsights.com/reports/dengue-vaccines-market/table-of-content

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries: sales@futuremarketinsights.com

For Media Enquiries: press@futuremarketinsights.com

Leave a comment

Your email address will not be published. Required fields are marked *